Skip to main content

Table 3 Visit schedule

From: Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial

 Selection visit
(from − 3 months to day 0)
Baseline visit
(day 0)
Treatment visit
(day 7 ± 2)
Treatment visit
(day 15 ± 3)
Treatment visit
(day 28 ± 4)
End of treatment visit
(day 60 ± 7)
Side effect visit
(not scheduled)
Follow-up visit
(months 4, 6, and 8)
Final visit
(month 12)
Informed consentx        
Demographic datax        
Pathological backgroundx        
Toxic habitsx        
Chagas disease historyx        
Concomitant medicationxxxxxxxxx
Directed anamnesisxxxxxxxxx
Physical examinationxxxxxxxxx
Pregnancy test x       
Hematologyx xxxxx  
Biochemistryx xxxxx  
HLAx        
Chest x-rayx        
EKGx        
PK   x xx  
Serologyx       x
PCRx xxxx xx
Other complementary testsx        
Adverse events xxxxxx  
Randomizationx        
Study medication xxxxx   
  1. Abbreviations: EKG Electrocardiogram, HLA Human leukocyte antigen, PCR Polymerase chain reaction, PK Pharmacokinetics